Aptamer Group has partnered with AstraZeneca to develop a siRNA delivery vehicle for targeting fibrotic liver cells. Following the positive results from the study so far, this phase of this research will explore the potential of the non-viral delivery vehicle and its applicability with a tool siRNA.
Under the partnership, Aptamer will explore using its Optimer vehicles to deliver siRNAs provided by AstraZeneca to liver cells. If successful, this new development could improve current cell and tissue-targeting methods. This approach aligns with Aptamer's strategy to develop binders that can provide long-term value by addressing critical needs in the tissue-targeting area.
UK-based Aptamer Group specializes in developing and providing aptamer-based technologies, branded as Optimer binders. Due to their high affinity, specificity, and stability, these binders are utilized in research, diagnostics, and therapeutic applications. The company leverages its proprietary Optimer technology to create high-performance binders that can be applied in numerous biological processes and diagnostic tests. Its offerings include custom Optimer selection and development services to facilitate innovations in the life sciences sector.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.